Darusentan
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 12.5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.126.841 |
Chemical and physical data | |
Formula | C22H22N2O6 |
Molar mass | 410.426 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist.[1] Gilead Colorado, a subsidiary of Gilead Sciences,[2] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[3]
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints.[4]
See also
References
- ^ Enseleit F, Lüscher TF, Ruschitzka F (August 2010). "Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension" (PDF). Therapeutic Advances in Cardiovascular Disease. 4 (4): 231–40. doi:10.1177/1753944710373785. PMID 20660536. S2CID 22533124.
- ^ Gilead Sciences[permanent dead link]
- ^ "Darusentan - Gilead Sciences". Adis Insight. Springer Nature Switzerland AG.
- ^ Clinical trial number NCT00389675 for "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension (Darusentan)" at ClinicalTrials.gov
Categories:
- All articles with dead external links
- Articles with dead external links from January 2024
- Articles with permanently dead external links
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Endothelin receptor antagonists
- Experimental drugs
- Lactims
- Carboxylic acids
- Diphenylmethanol ethers
- Aromatic ethers
- All stub articles
- Cardiovascular system drug stubs
- Antineoplastic and immunomodulating drug stubs